GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Zenas Biopharma Inc
The value of Zenas Biopharma, a private biotech company focused on treating autoimmune diseases, is determined by the progress of its clinical programs. The potential share price after the IPO will depend on the results of trials and the potential of its drugs in a competitive market.
Share prices of companies in the market segment - Pharma immune
Zenas Biopharma (ZBIO) is a global clinical-stage biopharmaceutical company focused on the development and commercialization of immunotherapeutic agents for the treatment of autoimmune diseases. We classify it in the Pharmaceuticals/Immunology sector. The chart below reflects the dynamics of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Zenas Biopharma is a global biopharmaceutical company focused on the development and commercialization of immunotherapeutic drugs. As a promising player, it is part of the market reflected in the GURU.Markets index. The chart below shows the overall dynamics of this innovative sector.
Change in the price of a company, segment, and market as a whole per day
ZBIO - Daily change in the company's share price Zenas Biopharma Inc
Shares of Zenas Biopharma, a biopharmaceutical company specializing in immunology, are highly volatile. Change_co measures the market's reaction to clinical trial data. This metric is an essential component in building valuation models for cutting-edge companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
The biotech sector in which Zenas Biopharma Inc operates is highly dynamic. This chart reflects the industry's average volatility. It serves as a benchmark for assessing how sensitive Zenas's drug development business is to general trends and clinical trial news.
Daily change in the price of a broad market stock, index - GURU.Markets
Zenas BioPharma is a privately held biopharmaceutical company specializing in immune-diseases treatments. Its potential IPO will depend heavily on the market's appetite for biotech innovation, as reflected in the overall volatility chart below.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Zenas Biopharma Inc
Zenas is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Zenas BioPharma, a private biotech company, develops drugs to treat autoimmune diseases. Its growth depends on success in clinical trials. Its valuation reflects investor confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Zenas Biopharma is privately held and not publicly traded. Its market performance cannot be analyzed. As a biotechnology company focused on immunology, its value is determined solely by clinical trial results and scientific breakthroughs, not by economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Zenas Biopharma Inc
Zenas's performance as a biopharmaceutical company will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of its clinical trials for autoimmune disease treatments, the success of which will determine its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Zenas Biopharma is a biotech company developing a portfolio of antibodies for the treatment of autoimmune diseases. Its strategy is to acquire and develop promising drugs from other companies. The chart below shows the general sentiment in the immunopharma sector, where Zenas is building its business.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Zenas Biopharma Inc. is a clinical-stage biotech company focused on autoimmune diseases. Its value is determined by the potential of its drugs under development. Its stock price is entirely dependent on clinical trial news and has no correlation with overall market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Zenas Biopharma Inc
Shares of Zenas Biopharma, a clinical-stage biotech company, have been experiencing extreme weekly volatility. Any news regarding the progress of its autoimmune disease drug trials could trigger sharp and significant price movements, reflecting the high risks.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Zenas Biopharma shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. The chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech companies like Zenas Biopharma often live in their own world, isolated from broader market fluctuations. Their stocks' fortunes are determined by clinical trial news, not inflation reports. The chart will show how often their stocks move against the broader market tide.
Market capitalization of the company, segment and market as a whole
ZBIO - Market capitalization of the company Zenas Biopharma Inc
Zenas Biopharma's market capitalization chart visualizes the company's hopes for creating a global biopharmaceutical company through licensing and development of promising drugs. It reflects investor valuations of its immunology drug pipeline. Its speculative dynamics tell the story of how the market weighs the potential of its scientific platform against the management team's experience.
ZBIO - Share of the company's market capitalization Zenas Biopharma Inc within the market segment - Pharma immune
Zenas Biopharma is a global biotech company developing a broad portfolio of drugs to treat immune diseases. Its market share is based on its strategy of acquiring and developing promising candidates. The chart shows how the market perceives its ability to create value from a diversified portfolio.
Market capitalization of the market segment - Pharma immune
Zenas Biopharma is a global biopharmaceutical company developing immunotherapeutic drugs. The chart below shows the overall market capitalization of the sector. Its growth reflects the enormous hope that we can manipulate the immune system to treat a wide range of diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotech companies visible on the chart are developing new treatments for autoimmune diseases. Zenas Biopharma has a pipeline of experimental drugs for a wide range of such diseases. Its market cap represents a risky bet on its clinical programs and potential for blockbusters.
Book value capitalization of the company, segment and market as a whole
ZBIO - Book value capitalization of the company Zenas Biopharma Inc
Zenas Biopharma's book value represents capital for the development of immunological drugs. Currently in clinical trials, the company uses its financial assets, reflected in the chart, to advance its portfolio of antibodies targeting autoimmune diseases.
ZBIO - Share of the company's book capitalization Zenas Biopharma Inc within the market segment - Pharma immune
Zenas Biopharma, a clinical-stage biopharmaceutical company, focuses on immunology. Its share of the sector's assets is minimal, consisting of R&D assets. Its value lies in its pipeline of potential drugs, not its physical assets.
Market segment balance sheet capitalization - Pharma immune
Zenas Biopharma is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Zenas uses a smart model: it licenses promising drugs and invests in their clinical development, acting as an R&D company.
Book value of all companies included in the broad market index - GURU.Markets
Zenas Biopharma is a global biopharmaceutical company developing immunotherapeutic drugs. Its book value is the capital it uses to conduct clinical trials of its pipeline of candidates targeting autoimmune diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Zenas Biopharma Inc
Zenas Biopharma is a biotechnology company. Its market capitalization is a premium to its cash flow, reflecting investors' bet on the success of its portfolio of immunology drugs acquired from other companies.
Market to book capitalization ratio in a market segment - Pharma immune
Zenas Biopharma is a global biotechnology company developing immunotherapeutic drugs. Its value is based on the potential of its clinical pipeline. The chart shows the premium investors place on its scientific potential and strategy compared to its current tangible assets.
Market to book capitalization ratio for the market as a whole
Zenas Biopharma is a biotechnology company developing drugs to treat autoimmune diseases. As a private company, its high valuation relative to the public market would reflect the potential of its lead drug candidates and investors' confidence in its ability to capture a significant share of a large and growing market.
Debts of the company, segment and market as a whole
ZBIO - Company debts Zenas Biopharma Inc
Zenas Biopharma is a biotechnology company developing immunological drugs. While in clinical trials, the company relies on external funding. This chart shows how Zenas manages its capital, raising funds to conduct expensive research and development to bring new treatments for autoimmune diseases to market.
Market segment debts - Pharma immune
Zenas Biopharma is a clinical-stage biopharmaceutical company focused on developing drugs for autoimmune diseases. Its funding is entirely dependent on equity capital. This chart reflects its financial position and ability to continue expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Zenas Biopharma Inc
Zenas Biopharma is a global clinical-stage biotechnology company developing drugs to treat autoimmune diseases. This chart shows its financial structure. For a company without sales revenue, debt is a significant risk, and its ability to continue research is directly dependent on raising equity capital.
Market segment debt to market segment book capitalization - Pharma immune
Zenas Biopharma is a clinical-stage biotech company developing treatments for autoimmune diseases. This process requires significant and long-term investment. The chart shows the overall debt burden in the pharmaceutical industry. It provides context for understanding Zenas's financial strategy as it moves toward potential commercialization.
Debt to book value of all companies in the market
Zenas Biopharma Inc. is a biotech company focused on developing drugs for autoimmune diseases. Currently in clinical trials, it has no revenue and is entirely dependent on investor capital. This chart clearly shows that the debt market is closed to such companies, and their survival depends on the success of their clinical data and faith in their science.
P/E of the company, segment and market as a whole
P/E - Zenas Biopharma Inc
For Zenas Biopharma, a clinical-stage biopharmaceutical company, the P/E ratio is irrelevant. The company has no profit, and its valuation on this chart is arbitrary. Its true value lies in the potential of its scientific developments in treating immune diseases and investors' faith in their success.
P/E of the market segment - Pharma immune
Zenas Biopharma is a global clinical-stage biopharmaceutical company developing immunotherapeutic drugs for the treatment of autoimmune and inflammatory diseases. This chart shows the average valuation for the sector, providing investors with context for evaluating Zenas's scientific potential and portfolio.
P/E of the market as a whole
Zenas Biopharma (privately held, ticker symbol ZBIO may be misleading) is a biotech developing drugs for the treatment of autoimmune diseases. Its valuation is a pure bet on the success of its clinical programs. Overall market sentiment, reflected in this chart, is completely irrelevant. Its fate depends on research data, not inflation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Zenas Biopharma Inc
Zenas Biopharma is a clinical-stage biotechnology company focused on developing immunotherapeutic drugs for the treatment of autoimmune diseases. Its value is based on the future potential of its pipeline. This chart reflects investors' confidence in the company's scientific approach and the commercial prospects of its future drugs.
%20P%2FE%20Zenas%20Biopharma%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Zenas-Biopharma-Inc&v=1772681558306 "Chart of the company's future (projected) P/E Zenas Biopharma Inc")
Future (projected) P/E of the market segment - Pharma immune
Zenas Biopharma is a global clinical-stage biopharmaceutical company developing immunotherapy. The chart reflects average profitability expectations for the biotech sector. ZBIO's position relative to this benchmark reflects investors' bet on its strategy of acquiring and developing promising drug candidates for the treatment of autoimmune diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772681558325 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Zenas Biopharma Inc. is a biopharmaceutical company focused on immunology. Like many companies in clinical development, its value is based on expectations of future breakthroughs. This chart, showing the general risk appetite of investors, defines the investment climate for raising capital for high-cost research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772681558333 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Zenas Biopharma Inc
Zenas Biopharma is a global biopharmaceutical company developing immunotherapeutic drugs. Its current financial schedule is driven by extensive clinical trials worldwide. Potential profit is entirely dependent on the successful development and commercialization of new drugs.
Profit of companies in the market segment - Pharma immune
Zenas Biopharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for the treatment of autoimmune diseases. Its portfolio consists of potentially best-in-class molecules. This chart shows the overall profitability of the immunopharmaceutical industry, reflecting the investment appetite for innovative treatments and their commercial potential.
Overall market profit
Zenas Biopharma is a global biotech company developing immunotherapeutic drugs. Like other clinical-stage companies, its value is determined by the potential of its scientific developments, not by current economic conditions. However, the overall market growth, visible in this chart, creates a favorable environment for attracting funding for expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Zenas Biopharma Inc
Zenas Biopharma is a clinical-stage biotechnology company focused on developing therapeutics for autoimmune diseases. Its future depends on the success of clinical trials. This chart reflects analysts' speculative expectations regarding the scientific and commercial potential of its pipeline of drug candidates.
%20profit%20of%20the%20company%20Zenas%20Biopharma%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Zenas-Biopharma-Inc&v=1772681558356 "Graph of future (projected) profit of the company Zenas Biopharma Inc")
Future (predicted) profit of companies in the market segment - Pharma immune
Zenas Biopharma is a clinical-stage biotech company developing antibody-based therapies for autoimmune diseases. Its pipeline aims to create a global company in this field. Its future depends on the success of its trials. This chart reflects forecasts for the entire biotech sector, providing context for assessing Zenas Biopharma's ambitious strategy and risks.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772681558359 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Zenas Biopharma is a global biopharmaceutical company developing immunotherapeutic drugs. Like other clinical-stage companies in this sector, its prospects are determined by research success rather than macroeconomic indicators. This earnings chart is not meaningful for assessing its potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772681558369 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Zenas Biopharma Inc
Zenas Biopharma is a global clinical-stage biopharmaceutical company focused on immunotherapy development. Without sales revenue, this chart reflects solely the market assessment of its development pipeline. Its performance is directly dependent on clinical trial results and the global market potential of its products.
P/S market segment - Pharma immune
Zenas Biopharma is a clinical-stage biotech company focused on developing immunotherapies for the treatment of autoimmune diseases. Future revenue depends on the success of its drugs. This pharma chart compares investor expectations for Zenas's pipeline with those of other companies working in the immunology field.
P/S of the market as a whole
Zenas Biopharma is a clinical-stage biotech company focused on developing immunotherapeutic drugs for the treatment of autoimmune diseases. This market revenue valuation chart helps understand how investors value the company's portfolio, which targets a wide range of immune-related diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Zenas Biopharma Inc
Zenas Biopharma is a global clinical-stage biopharmaceutical company focused on developing immunotherapeutics for the treatment of autoimmune diseases. This chart shows how the market assesses the future commercial potential of its pipeline, placing a premium on clinical trial success and market entry.
%20P%2FS%20Zenas%20Biopharma%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Zenas-Biopharma-Inc&v=1772681558397 "The graph of the company's future (projected) P/S Zenas Biopharma Inc")
Future (projected) P/S of the market segment - Pharma immune
Zenas Biopharma is a global clinical-stage biopharmaceutical company focused on developing immunotherapeutic drugs for the treatment of autoimmune and inflammatory diseases. The company's valuation is based on investors' confidence in its acquisition and development strategy and the potential of its pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772681558404 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Zenas Biopharma Inc. is a clinical-stage biotechnology company focused on immunological diseases. Its value reflects expectations of future scientific breakthroughs. This chart reflects revenue forecasts for existing businesses, while Zenas's potential to create entirely new markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772681558415 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Zenas Biopharma Inc
Zenas Biopharma is a global clinical-stage biopharmaceutical company focused on developing immunotherapies. The company currently has no commercial products and, therefore, no revenue from their sales. Any revenue shown in the chart may be due to funding from partners.
Sales of companies in the market segment - Pharma immune
Zenas Biopharma (ZBIO) is a global biopharmaceutical company focused on the development and commercialization of immunotherapeutic drugs. Its portfolio includes candidates for the treatment of a wide range of autoimmune diseases. This chart shows revenue in the immunology pharmaceutical sector, where Zenas strives to become a leader by developing innovative treatments.
Overall market sales
Zenas Biopharma is a global biotech company developing immunotherapeutic drugs. Its growth depends on successful clinical trials and its ability to raise capital. This chart, reflecting the overall state of financial markets, influences the investment climate. During periods of growth, investors are more willing to fund promising biotech companies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Zenas Biopharma Inc
Zenas Biopharma is a biotechnology company developing drugs for the treatment of autoimmune diseases. Its pipeline includes several candidates in various stages of clinical trials. Future revenue depends on the success of these trials. This chart reflects analyst forecasts, which are estimates of the overall commercial potential of its pipeline.
%20sales%20of%20the%20company%20Zenas%20Biopharma%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Zenas-Biopharma-Inc&v=1772681558463 "Schedule of future (projected) sales of the company Zenas Biopharma Inc")
Future (projected) sales of companies in the market segment - Pharma immune
Zenas Biopharma is a biopharmaceutical company developing drugs to treat autoimmune diseases. This forecast chart reflects the potential future revenue from their pipeline of drug candidates. This is an analyst's view of the commercial prospects of their innovative approaches to treating immune-related diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772681558468 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Zenas Biopharma is a clinical-stage biotechnology company specializing in the development of immunotherapeutic drugs. Its value is based on the potential of its pipeline. This chart, reflecting overall market sentiment, impacts the availability of capital for funding lengthy and expensive clinical trials in immunology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772681558567 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Zenas Biopharma Inc
Zenas Biopharma is a clinical-stage biotechnology company developing drugs for the treatment of autoimmune diseases. Its current financial performance reflects significant investments in research and clinical trials. The chart shows profitability, which is a guarantee of future success should its innovative therapies be approved.
Market segment marginality - Pharma immune
Zenas Biopharma is a global clinical-stage biopharmaceutical company focused on immunotherapy development. This chart reflects its operating expenses. As with other biotech companies without revenue, the dynamics of this metric are important for assessing the effectiveness of capital management during drug development.
Market marginality as a whole
Zenas Biopharma is a global clinical-stage biotechnology company developing therapies for autoimmune diseases. Its valuation and prospects depend on research results. This gross profitability chart reflects the investment climate. In a favorable economic environment, companies can more easily raise capital to conduct expensive trials.
Employees in the company, segment and market as a whole
Number of employees in the company Zenas Biopharma Inc
Zenas Biopharma is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its small but growing team consists of experts in immunology and clinical development. Growth on this chart indicates progress in clinical trials of its pipeline.
Share of the company's employees Zenas Biopharma Inc within the market segment - Pharma immune
Zenas Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. At this stage, its primary asset is its team of scientists and clinicians advancing its pipeline of drug candidates. This graph reflects the scale of human investment in research to address complex medical challenges.
Number of employees in the market segment - Pharma immune
Zenas Biopharma is a global biotechnology company developing immunotherapeutic drugs. The employment dynamics in the immunopharmaceutical sector, shown here, illustrate the enormous investment and scientific interest in this field. For Zenas, this means working in a highly competitive yet promising environment, where new treatments for autoimmune diseases are constantly emerging.
Number of employees in the market as a whole
Zenas BioPharma is a clinical-stage biopharmaceutical company developing immunological therapies. Its team of scientists is focused on advancing its pipeline of drugs through clinical trials. Hiring is driven by research milestones rather than economic cycles, as they are on the hunt for top talent.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Zenas Biopharma Inc (ZBIO)
Zenas Biopharma is a biotechnology company developing drugs to treat autoimmune diseases. Its entire capital comes from its portfolio of promising molecules and research results. This metric reflects how the market evaluates the potential of these future drugs, where enormous value is generated by a small team of highly qualified scientists.
%20of%20the%20company%20Zenas%20Biopharma%20Inc%20(ZBIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Zenas-Biopharma-Inc-ZBIO&v=1772681558763 "Chart of market capitalization per employee (in thousands of dollars) of the company Zenas Biopharma Inc (ZBIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Zenas Biopharma is a clinical-stage biotech company focused on developing drugs to treat autoimmune diseases. Its market capitalization reflects investors' faith in its scientific platform and pipeline of candidates. The chart shows the enormous future value the market attributes to its research.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772681558776 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Zenas Biopharma is a clinical-stage biotech company focused on developing drugs for the treatment of autoimmune diseases. This chart reflects the market valuation of its promising pipeline. The company's entire value is based on the hope of successful clinical trials. This indicator demonstrates the value the market places on the work of its scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772681558777 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Zenas Biopharma Inc (ZBIO)
Zenas Biopharma is a clinical-stage biotech company focused on immunological diseases. Like many of its peers in the sector, its profits are negative. This chart shows the investment (loss) per employee spent on clinical trials and development of its pipeline.
%20Chart%20Zenas%20Biopharma%20Inc%20(ZBIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Zenas-Biopharma-Inc-ZBIO&v=1772681558790 "Company Profit Per Employee (in thousands of dollars) Chart Zenas Biopharma Inc (ZBIO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Zenas Biopharma (ZBIO) is a clinical-stage biotechnology company developing drugs for the treatment of autoimmune diseases. Like other R&D companies, this metric is negative (loss per employee), reflecting the high cost of conducting global clinical trials.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772681558807 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Zenas Biopharma is a biotech company developing immunotherapy for the treatment of autoimmune diseases. The company is in the clinical stage and is not profitable. This chart is important for understanding that in the immunology sector, employees (scientists) are a cost center, generating high-potential intellectual property.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772681558808 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Zenas Biopharma Inc (ZBIO)
Zenas Biopharma is a global biopharmaceutical company focused on developing immunotherapeutic drugs. Being in clinical development, it has no commercial revenue yet. This graph will show zero values, which is typical for R&D companies whose value lies in the potential of their scientific portfolio.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Zenas-Biopharma-Inc-ZBIO&v=1772681558810 "Sales chart per company employee Zenas Biopharma Inc (ZBIO)")
Sales per employee in the market segment - Pharma immune
Zenas Biopharma (ZBIO) is a clinical-stage biotech company focused on developing treatments for immunological diseases. This chart shows the average revenue per employee in the sector. It is important for assessing the efficiency of capital utilization and personnel structure compared to other biotech companies.
Sales per employee for the market as a whole
Zenas Biopharma (ZBIO) is a biotechnology company focused on developing and commercializing treatments for autoimmune diseases. The company is in the clinical stage, meaning its revenue, if any, is minimal (from partnerships), while its R&D and personnel costs are significant. This metric reflects the current cost of research per scientist.
Short shares by company, segment and market as a whole
Shares shorted by company Zenas Biopharma Inc (ZBIO)
Zenas Biopharma (ZBIO) is a clinical-stage biotech developing treatments for autoimmune diseases. This chart shows bearish sentiment. The high level of short positions reflects significant risks: investors may doubt that ZBIO's drugs will be more effective or safer than existing treatments in this highly competitive market. (340)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Zenas-Biopharma-Inc-ZBIO&v=1772681558847 "Short Shares Chart for the Company Zenas Biopharma Inc (ZBIO)")
Shares shorted by market segment - Pharma immune
Zenas is a clinical-stage biotech company developing therapeutics (antibodies) for the treatment of autoimmune diseases. This chart reflects the overall sentiment in the sector, reflecting investor skepticism toward biotech companies operating in the highly competitive field of immunology.
Shares shorted by the overall market
Zenas Biopharma (ZBIO) is a global biotech company that acquires and develops promising drugs for the treatment of immune diseases. Their model is R&D "arbitrage." This chart illustrates skepticism about their portfolio. "Bears" may not believe in the success of the drugs they licensed or believe the company overpaid for these assets and will never recoup their investment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Zenas Biopharma Inc (ZBIO)
Zenas Biopharma is a clinical-stage biotech company. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks or a general risk-aversion trend in biotech, indicating potential pessimism.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Zenas-Biopharma-Inc-ZBIO&v=1772681558883 "RSI 14 indicator chart for the company's stock Zenas Biopharma Inc (ZBIO)")
RSI 14 Market Segment - Pharma immune
Zenas (ZBIO) is a biotech company developing antibodies to treat rare immune diseases. The RSI_14_Seg for "Pharma immune" shows whether the entire biotech segment is overheated. The chart helps us understand whether ZBIO's volatility is a reaction to its clinical trials or simply general hype in the sector.
RSI 14 for the overall market
Zenas Biopharma (ZBIO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ZBIO (Zenas Biopharma Inc)
Zenas Biopharma (ZBIO) is a clinical-stage biotech developing treatments for autoimmune diseases. This chart shows the average 12-month forecast, reflecting analysts' confidence in the company's scientific platform and its potential to develop new therapeutics.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ZBIO-Zenas-Biopharma-Inc&v=1772681558907 "A chart showing analyst consensus forecasts for the expected stock price. ZBIO (Zenas Biopharma Inc)")
The difference between the consensus estimate and the actual stock price ZBIO (Zenas Biopharma Inc)
Zenas Biopharma is a biotech company developing a pipeline of drug candidates for the treatment of autoimmune diseases. This chart shows the difference between the market valuation and analyst consensus estimates. It highlights the potential experts see in their clinical development pipeline and future partnerships.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ZBIO-Zenas-Biopharma-Inc&v=1772681558923 "A chart showing the difference between the consensus forecast and the actual stock price. ZBIO (Zenas Biopharma Inc)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Zenas Biopharma is a clinical-stage biotech company developing a portfolio of antibodies for the treatment of rare and systemic autoimmune diseases. This chart shows analyst expectations across the immunopharma sector. It reflects the confidence of experts in the success of the company's R&D pipeline and platform.
Analysts' consensus forecast for the overall market share price
Zenas Biopharma is a biotech company specializing in the development of treatments for autoimmune diseases. Their strategy is to acquire and develop promising drugs. This chart shows overall market sentiment. For Zenas, as an R&D company, it's important to understand how overall risk appetite (sentiment) impacts their ability to fund clinical trials. (348)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Zenas Biopharma Inc
Zenas Biopharma (ZBIO) is a clinical-stage biotech focused on developing drugs for the treatment of autoimmune diseases. This chart represents pure R&D value. Its valuation is not tied to current revenue but reflects investors' faith in their scientific platform and the potential of their lead drug candidate in this competitive field.
AKIMA Market Segment Index - Pharma immune
Zenas Biopharma (ZBIO) is a global clinical-stage biotech focused on immunology; the company is developing a portfolio of antibodies for the treatment of autoimmune diseases. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this R&D platform (ZBIO) differentiate it from the average pharma company?
The AKIM Index for the overall market
Zenas BioPharma is a biotech company developing immunological treatments for autoimmune diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific company, which is striving to become a global player in immunology, compares to overall economic trends.
